RxDoctor Payments Data

Annette Morales

Family Health · Bayonne, NJNPI 1295271831

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $559, more than ten times the $25 reported in 2022.

$1,006in general payments, 2019–2025

Across 57 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$206
  • Novo Nordisk$194
  • Novartis$114
  • GSK$110
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$83
  • Merck$66
  • plus $234 from 11 others

What the payments were for

  • Food & beverage$1,006100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few family health providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$16,695
Medicare patients
109
Services billed
188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$50,305
OzempicSemaglutide16$17,844
MounjaroTirzepatide12$14,633
Metoprolol Succinate76$1,125
Levothyroxine Sodium18$792
Albuterol Sulfate HfaAlbuterol Sulfate15$753
Atorvastatin Calcium73$643
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide28$499
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide20$456
ClopidogrelClopidogrel Bisulfate38$355
Omeprazole18$334
Losartan Potassium44$236
Amlodipine Besylate42$225
Rosuvastatin Calcium18$222
Potassium Chloride19$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$194$17,84416 claims
Lilly USA, LLCMounjaro$36$14,63312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family health providers in New Jerseyon file to place this against a meaningful peer group, so we don't.

Other family health in Bayonne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →